Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN versus HISPRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN versus HISPRIL.
CLARITIN vs HISPRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonistic activity. It inhibits histamine release from mast cells and reduces allergic responses.
HISPRIL (lisinopril) is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and afterload.
10 mg orally once daily for adults and children ≥6 years.
10 mg orally once daily, increased to 20 mg once daily after 2-4 weeks if needed.
None Documented
None Documented
Terminal elimination half-life 27 hours (range 22-30 hours); clinical context: allows once-daily dosing, steady state reached in 5-7 days
The terminal elimination half-life of HISPRIL is approximately 12-15 hours in patients with normal renal function, supporting twice-daily dosing. In moderate to severe renal impairment (CrCl <30 mL/min), half-life is prolonged up to 30-40 hours, necessitating dose interval adjustment.
Renal 40% as metabolites, fecal 40% as metabolites, biliary <5% as unchanged drug
HISPRIL is predominantly excreted renally, with approximately 60-70% of an administered dose recovered unchanged in urine over 48 hours. Hepatic metabolism accounts for <10% of elimination, and fecal excretion contributes <5%.
Category C
Category C
Antihistamine
Antihistamine